Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 169
Filtrar
1.
Trans R Soc Trop Med Hyg ; 116(9): 763-766, 2022 09 10.
Artículo en Inglés | MEDLINE | ID: mdl-35537855

RESUMEN

A cholera outbreak in Blue Nile and Sennar states, south-eastern and southern Sudan, took place during September-December 2019. An outbreak surveillance sample collection was made. Vibrio cholerae O1 Ogawa was isolated from clinical samples of all confirmed 200 and 132 cases in Blue Nile state and Sennar state, respectively. The case fatality rate was higher in Blue Nile state, 4% compared with only 2.3% in Sennar state. The Euvichol-Plus oral cholera vaccine was rapidly deployed for the first time in Sudan to the most at-risk populations in the two affected states, 1 471 188 and 1 546 542 individuals in Sennar and Blue Nile states, respectively. The rapid deployment of cholera vaccines as the major prevention and control strategy was successful and helped greatly with the containment of this epidemic. In-depth genomics studies are crucial for understanding the disease dynamics in Sudan by identifying locally circulating strains of the bacteria and further improving prevention and control strategy by characterising the susceptibility and resistance of these locally circulating strains to currently used antibiotics.


Asunto(s)
Vacunas contra el Cólera , Cólera , Vibrio cholerae O1 , Antibacterianos/uso terapéutico , Cólera/epidemiología , Cólera/microbiología , Cólera/prevención & control , Vacunas contra el Cólera/uso terapéutico , Brotes de Enfermedades/prevención & control , Humanos
2.
Am J Trop Med Hyg ; 105(3): 622-626, 2021 07 08.
Artículo en Inglés | MEDLINE | ID: mdl-34237020

RESUMEN

Cholera remains a significant public health burden worldwide, and better methods for monitoring cholera incidence would enhance the effectiveness of public health interventions. The serum bactericidal assay (SBA) has been used extensively for Vibrio cholerae vaccine assessments and serosurveillance. Current SBA approaches for V. cholerae rely on colony enumeration or optical density (OD600nm) readings to measure viable bacteria following complement-mediated lysis. These methods provide titer values that are constrained to discrete dilution values and rely on bacterial outgrowth, which is time consuming and prone to variation. Detection of bacterial proteins following complement-mediated lysis presents a faster and potentially less variable alternative approach independent of bacterial outgrowth. Here, we present an SBA that measures luciferase luminescence driven by lysis-released adenylate kinase. This approach is faster and less variable than growth-dependent SBAs and directly measures continuous titer values. This novel SBA method can potentially be applied to other bacteria of interest.


Asunto(s)
Anticuerpos Antibacterianos/inmunología , Cólera/epidemiología , Determinación de Anticuerpos Séricos Bactericidas/métodos , Vibrio cholerae/inmunología , Cólera/inmunología , Cólera/prevención & control , Vacunas contra el Cólera/uso terapéutico , Análisis Costo-Beneficio , Monitoreo Epidemiológico , Humanos , Inmunogenicidad Vacunal , Mediciones Luminiscentes , Reproducibilidad de los Resultados , Estudios Seroepidemiológicos , Factores de Tiempo
3.
Am J Epidemiol ; 190(9): 1882-1889, 2021 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-33728441

RESUMEN

The test-negative study design is often used to estimate vaccine effectiveness in influenza studies, but it has also been proposed in the context of other infectious diseases, such as cholera, dengue, or Ebola. It was introduced as a variation of the case-control design, in an attempt to reduce confounding bias due to health-care-seeking behavior, and has quickly gained popularity because of its logistic advantages. However, examination of the directed acyclic graphs that describe the test-negative design reveals that without strong assumptions, the estimated odds ratio derived under this sampling mechanism is not collapsible over the selection variable, such that the results obtained for the sampled individuals cannot be generalized to the whole population. In this paper, we show that adjustment for severity of disease can reduce this bias and, under certain assumptions, makes it possible to unbiasedly estimate a causal odds ratio. We support our findings with extensive simulations and discuss them in the context of recently published cholera test-negative studies of the effectiveness of cholera vaccines.


Asunto(s)
Infecciones/patología , Proyectos de Investigación , Índice de Severidad de la Enfermedad , Vacunas/uso terapéutico , Sesgo , Estudios de Casos y Controles , Cólera/patología , Cólera/prevención & control , Vacunas contra el Cólera/uso terapéutico , Humanos , Control de Infecciones/métodos , Modelos Estadísticos , Oportunidad Relativa , Aceptación de la Atención de Salud/estadística & datos numéricos , Resultado del Tratamiento
4.
Lancet Infect Dis ; 21(3): e37-e48, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33096017

RESUMEN

Globally, cholera epidemics continue to challenge disease control. Although mass campaigns covering large populations are commonly used to control cholera, spatial targeting of case households and their radius is emerging as a potentially efficient strategy. We did a Scoping Review to investigate the effectiveness of interventions delivered through case-area targeted intervention, its optimal spatiotemporal scale, and its effectiveness in reducing transmission. 53 articles were retrieved. We found that antibiotic chemoprophylaxis, point-of-use water treatment, and hygiene promotion can rapidly reduce household transmission, and single-dose vaccination can extend the duration of protection within the radius of households. Evidence supports a high-risk spatiotemporal zone of 100 m around case households, for 7 days. Two evaluations separately showed reductions in household transmission when targeting case households, and in size and duration of case clusters when targeting radii. Although case-area targeted intervention shows promise for outbreak control, it is critically dependent on early detection capacity and requires prospective evaluation of intervention packages.


Asunto(s)
Cólera/prevención & control , Cólera/terapia , Epidemias , Análisis Espacio-Temporal , Profilaxis Antibiótica , Manejo de Caso/normas , Cólera/transmisión , Vacunas contra el Cólera/uso terapéutico , Geografía , Implementación de Plan de Salud/normas , Humanos , Higiene , Modelos Teóricos , Purificación del Agua/normas
5.
Vaccimonitor (La Habana, Print) ; 29(3)sept.-dic. 2020. graf
Artículo en Inglés | CUMED, LILACS | ID: biblio-1139857

RESUMEN

Cholera is endemic in over 50 countries with an estimated mortality of 100,000-120,000. Vaccination is considered the complementary key to prevent and control cholera; therefore, alternative vaccine preparations are needed. Toxin Co-regulated Pilus is part of the toxR virulence regulon, which is necessary for colonization in the intestinal mucosa. In order to express Vibrio cholerae TcpA protein in Saccharomyces boulardii, the expression plasmid pYES2 was constructed by inserting tcpA gene isolated from local Vibrio cholerae Eltor Inaba isolates. The new construct was transferred into Saccharomyces boulardii cells and the expression of tcpA gene was induced from the GAL1 promoter by adding galactose to the medium. The SDS-PAGE and Western blot analysis showed the presence of TcpA in yeast. These results showed that Saccharomyces boulardii is a promising host to express Vibrio cholerae toxin TcpA as the first step in attempt to produce an oral Vibrio cholerae vaccine(AU)


El cólera es endémico en más de 50 países. Se estima una mortalidad entre 100.000 - 120.000 debido a esta enfermedad. La vacunación se considera una medida complementaria para prevenir y controlar el cólera, por lo tanto, se necesitan preparaciones vacunales alternativas a las existentes. El Pili corregulado con la toxina, es parte del regulón de virulencia toxR, y es necesario para la colonización en la mucosa intestinal. Para expresar la proteína tcpA de Vibrio cholerae en Saccharomyces boulardii, se construyó el plásmido de expresión pYES2 insertando el gen tcpA obtenido a partir de aislamientos locales de Vibrio cholerae El Tor Inaba. La nueva construcción se transfirió a las células de Saccharomyces boulardii y se indujo la expresión del gen tcpA a partir del promotor GAL1 mediante la adición de galactosa al medio. El análisis mediante SDS-PAGE y Western blot demostró la presencia de TcpA en levaduras. Los resultados demostraron que Saccharomyces boulardii es un hospedero prometedor para expresar el gen tcpA de Vibrio cholerae como el primer paso en el intento de producir una vacuna oral contra Vibrio cholerae(AU)


Asunto(s)
Humanos , Masculino , Femenino , Vacunas contra el Cólera/uso terapéutico , Cólera/mortalidad , Cólera/prevención & control , Infecciones por Escherichia coli , Saccharomyces boulardii/efectos de los fármacos
6.
BMJ Glob Health ; 5(1): e002000, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32133173

RESUMEN

Introduction: In August 2017, a cholera outbreak started in Muna Garage Internally Displaced Persons camp, Borno state, Nigeria and >5000 cases occurred in six local government areas. This qualitative study evaluated perspectives about the emergency response to this outbreak. Methods: We conducted 39 key informant interviews and focus group discussions, and reviewed 21 documents with participants involved with surveillance, water, sanitation, hygiene, case management, oral cholera vaccine (OCV), communications, logistics and coordination. Qualitative data analysis used thematic techniques comprising key words in context, word repetition and key sector terms. Results: Authorities were alerted quickly, but outbreak declaration took 12 days due to a 10-day delay waiting for culture confirmation. Outbreak investigation revealed several potential transmission channels, but a leaking latrine around the index cases' house was not repaired for more than 7 days. Chlorine was initially not accepted by the community due to rumours that it would sterilise women. Key messages were in Hausa, although Kanuri was the primary local language; later this was corrected. Planning would have benefited using exercise drills to identify weaknesses, and inventory sharing to avoid stock outs. The response by the Rural Water Supply and Sanitation Agency was perceived to be slow and an increased risk from a religious festival was not recognised. Case management was provided at treatment centres, but some partners were concerned that their work was not recognised asking, 'Who gets the glory and the data?' Nearly one million people received OCV and its distribution benefited from a robust infrastructure for polio vaccination. There was initial anxiety, rumour and reluctance about OCV, attributed by many to lack of formative research prior to vaccine implementation. Coordination was slow initially, but improved with activation of an emergency operations centre (EOC) that enabled implementation of incident management system to coordinate multisectoral activities and meetings held at 16:00 hours daily. The synergy between partners and government improved when each recognised the government's leadership role. Conclusion: Despite a timely alert of the outbreak, delayed laboratory confirmation slowed initial response. Initial responses to the outbreak were not well coordinated but improved with the EOC. Understanding behaviours and community norms through rapid formative research should improve the effectiveness of the emergency response to a cholera outbreak. OCV distribution was efficient and benefited from the polio vaccine infrastructure.


Asunto(s)
Cólera , Planificación en Desastres/organización & administración , Brotes de Enfermedades , Campos de Refugiados , Cólera/prevención & control , Cólera/terapia , Vacunas contra el Cólera/administración & dosificación , Vacunas contra el Cólera/uso terapéutico , Urgencias Médicas , Humanos , Nigeria , Refugiados
8.
BMC Infect Dis ; 19(1): 4, 2019 Jan 03.
Artículo en Inglés | MEDLINE | ID: mdl-30606126

RESUMEN

BACKGROUND: On 18th May 2017, State Ministry of Health of former Warrap State received a report from Tonj East County of an outbreak of acute watery diarrhoea and vomiting in Makuac payam. We conducted this investigation to confirm the causative organism and describe the epidemiology of the outbreak in order to support evidence-based control measures. METHODS: We defined a suspected case as a resident of Tonj East or Tonj North County with sudden onset of acute watery diarrhoea and vomiting between May 1 and October 15, 2017. A probable case was defined as a suspected case with a positive rapid test for Vibrio cholerae; a confirmed case was a probable case with a positive stool culture for V. cholerae. We conducted systematic case finding by visiting health facilities and villages in the affected payams. We reviewed patient records from 1 May 2017 to 15 October 2017, to identify suspected cholera case-patients. We conducted a descriptive epidemiologic study, examining the distribution of the cases. We computed the attack rates by age, sex, and payam of residence. Case fatality rate was calculated as the ratio of the total number of suspected cholera death to the total number of cholera case-patients. We conducted an oral cholera vaccination campaign after the peak of the outbreak to control and prevent the spread to other payams. RESULTS: We identified 1451 suspected cholera cases between May and October 2017. Of these, 81% (21/26) had a positive rapid diagnostic test for V. cholerae; out of the 16 rectal swabs transported to the National Public Laboratory, 88% (14/16) were confirmed to be V. cholerae O1 serotype Inaba. The epidemic curve shows continuous common source outbreak with several peaks. The mean age of the case-patients was 24 years (Range: 0.2-75y). The clinical presentations of the case-patients were consistent with cholera. Males had an attack rate of 9.9/10000. The highest attack rate was in ≥30y (14 per 10,000). Among the six payams affected, Makuac had the highest attack rate of 3/100. The case fatality rate (CFR) was 3.0% (44/1451). Paliang and Wunlit had an oral cholera vaccination coverage of ≥100%, while 4 payams had a vaccination coverage of < 90%. CONCLUSION: This was a continuous common source cholera outbreak caused by V. cholerae 01 sero type Inaba. We recommended strengthening of the surveillance system to improve early detection and effective response.


Asunto(s)
Cólera/epidemiología , Adolescente , Adulto , Niño , Preescolar , Cólera/etiología , Cólera/microbiología , Vacunas contra el Cólera/uso terapéutico , Diarrea/epidemiología , Diarrea/microbiología , Brotes de Enfermedades , Femenino , Humanos , Programas de Inmunización , Lactante , Masculino , Sudán del Sur/epidemiología , Vibrio cholerae/patogenicidad , Vómitos/epidemiología , Vómitos/microbiología , Adulto Joven
9.
Front Med ; 13(2): 213-228, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-29934743

RESUMEN

Cholera is a secretory diarrhoeal disease caused by infection with Vibrio cholerae, primarily the V. cholerae O1 El Tor biotype. There are approximately 2.9 million cases in 69 endemic countries annually, resulting in 95 000 deaths. Cholera is associated with poor infrastructure and lack of access to sanitation and clean drinking water. The current cholera epidemic in Yemen, linked to spread of V. cholerae O1 (Ogawa serotype), is associated with the ongoing war. This has devastated infrastructure and health services. The World Health Organization had estimated that 172 286 suspected cases arose between 27th April and 19th June 2017, including 1170 deaths. While there are three oral cholera vaccines prequalified by the World Health Organization, there are issues surrounding vaccination campaigns in conflict situations, exacerbated by external factors such as a global vaccine shortage. Major movements of people complicates surveillance and administration of double doses of vaccines. Cholera therapy mainly depends on rehydration, with use of antibiotics in more severe infections. Concerns have arisen about the rise of antibiotic resistance in cholera, due to mobile genetic elements. In this review, we give an overview of cholera epidemiology, virulence, antibiotic resistance, therapy and vaccines, in the light of the ongoing epidemic in Yemen.


Asunto(s)
Antibacterianos/uso terapéutico , Vacunas contra el Cólera/uso terapéutico , Cólera/tratamiento farmacológico , Cólera/prevención & control , Vibrio cholerae/efectos de los fármacos , ADN Bacteriano/genética , Brotes de Enfermedades , Farmacorresistencia Bacteriana Múltiple , Humanos , Pruebas de Sensibilidad Microbiana , Reacción en Cadena de la Polimerasa , Vibrio cholerae/aislamiento & purificación , Factores de Virulencia/genética , Yemen
10.
J Prev Med Hyg ; 60(4): E271-E285, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-31967084

RESUMEN

The burden of diarrheal diseases is very high, accounting for 1.7 to 5 billion cases per year worldwide. Typhoid fever (TF) and cholera are potentially life-threatening infectious diseases, and are mainly transmitted through the consumption of food, drink or water that have been contaminated by the feces or urine of subjects excreting the pathogen. TF is mainly caused by Salmonella typhi, whereas cholera is caused by intestinal infection by the toxin-producing bacterium Vibrio cholerae. These diseases typically affect low- and middle-income countries where housing is overcrowded and water and sanitation are poor, or where conflicts or natural disasters have led to the collapse of the water, sanitation and healthcare systems. Mortality is higher in children under 5 years of age. Regarding their geographical distribution, TF has a high incidence in sub-Saharan Africa, India and south-east Asia, while cholera has a high incidence in a few African countries, particularly in the Horn of Africa and the Arabian Peninsula. In the fight against these diseases, preventive measures are fundamental. With modern air travel, transmissible diseases can spread across continents and oceans in a few days, constituting a threat to global public health. Nowadays, people travel for many reasons, such as tourism and business. Several surveys have shown that a high proportion of travelers lack adequate information on safety issues, such as timely vaccination and prophylactic medications. The main objective of this overview is to provide information to help European travelers to stay healthy while abroad, and thus also to reduce the potential importation of these diseases and their consequent implications for public health and society. The preventive measures to be implemented in the case of travel to countries where these diseases are still endemic are well known: the adoption of safe practices and vaccinations. It is important to stress that an effective preventive strategy should be based both on vaccinations and on hygiene travel guidelines. Furthermore, the emergence of multidrug-resistant strains is becoming a serious problem in the clinical treatment of these diseases. For this reason, vaccination is the main solution.


Asunto(s)
Cólera/epidemiología , Enfermedad Relacionada con los Viajes , Fiebre Tifoidea/epidemiología , Antibacterianos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica , Azitromicina/uso terapéutico , Bicarbonatos/uso terapéutico , Cefalosporinas/uso terapéutico , Cólera/prevención & control , Cólera/terapia , Vacunas contra el Cólera/uso terapéutico , Ciprofloxacina/uso terapéutico , Agua Potable/microbiología , Farmacorresistencia Bacteriana , Enfermedades Endémicas , Epidemias , Europa (Continente) , Carga Global de Enfermedades , Glucosa/uso terapéutico , Humanos , Idarrubicina , Cloruro de Potasio/uso terapéutico , Prednisona , Lactato de Ringer/uso terapéutico , Saneamiento , Cloruro de Sodio/uso terapéutico , Viaje , Medicina del Viajero , Fiebre Tifoidea/prevención & control , Fiebre Tifoidea/terapia , Vacunas Tifoides-Paratifoides/uso terapéutico , Vidarabina/análogos & derivados
11.
PLoS One ; 13(10): e0198592, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30281604

RESUMEN

BACKGROUND: In addition to improving water, sanitation and hygiene (WASH) measures and optimal case management, the introduction of Oral cholera vaccine (OCV) is a complementary strategy for cholera prevention and control for vulnerable population groups. In October 2016, the Mozambique Ministry of Health implemented a mass vaccination campaign using a two-dose regimen of the Shanchol™ OCV in six high-risk neighborhoods of Nampula city, in Northern Mozambique. Overall 193,403 people were targeted by the campaign, which used a door-to-door strategy. During campaign follow-up, a population survey was conducted to assess: (1) OCV coverage; (2) frequency of adverse events following immunization; (3) vaccine acceptability and (4) reasons for non-vaccination. METHODOLOGY/PRINCIPAL FINDINGS: In the absence of a household listing and clear administrative neighborhood delimitations, we used geospatial technology to select households from satellite images and used the support of community leaders. One person per household was randomly selected for interview. In total, 636 individuals were enrolled in the survey. The overall vaccination coverage with at least one dose (including card and oral reporting) was 69.5% (95%CI: 51.2-88.2) and the two-dose coverage was 51.2% (95%CI: 37.9-64.3). The campaign was well accepted. Among the 185 non-vaccinated individuals, 83 (44.6%) did not take the vaccine because they were absent when the vaccination team visited their houses. Among the 451 vaccinated individuals, 47 (10%) reported minor and non-specific complaints, and 78 (17.3%) mentioned they did not receive any information before the campaign. CONCLUSIONS/SIGNIFICANCE: In spite of overall coverage being slightly lower than expected, the use of a mobile door-to-door strategy remains a viable option even in densely-populated urban settings. Our results suggest that campaigns can be successfully implemented and well accepted in Mozambique in non-emergency contexts in order to prevent cholera outbreaks. These findings are encouraging and complement the previous Mozambican experience related to OCV.


Asunto(s)
Vacunas contra el Cólera/uso terapéutico , Cólera/prevención & control , Administración Oral , Adolescente , Niño , Preescolar , Cólera/epidemiología , Vacunas contra el Cólera/administración & dosificación , Vacunas contra el Cólera/efectos adversos , Femenino , Humanos , Lactante , Masculino , Vacunación Masiva/estadística & datos numéricos , Mozambique/epidemiología , Encuestas y Cuestionarios , Cobertura de Vacunación/estadística & datos numéricos , Poblaciones Vulnerables/estadística & datos numéricos
12.
Vaccine ; 36(45): 6606-6614, 2018 10 29.
Artículo en Inglés | MEDLINE | ID: mdl-30314912

RESUMEN

Cholera, a diarrheal disease primarily affecting vulnerable populations in developing countries, is estimated to cause disease in more than 2.5 million people and kill almost 100,000 annually. An oral cholera vaccine (OCV) has been available globally since 2001; the demand for this vaccine from affected countries has however been very low, due to various factors including vaccine price and mode of administration. The low demand for the vaccine and limited commercial incentives to invest in research and development of vaccines for developing country markets has kept the global supply of OCVs down. Since 1999, the International Vaccine Institute has been committed to make safe, effective and affordable OCVs accessible. Through a variety of partnerships with collaborators in Sweden, Vietnam, India and South Korea, and with public and private funding, IVI facilitated development and production of two affordable and WHO-prequalified OCVs and together with other stakeholders accelerated the introduction of these vaccines for the global public-sector market.


Asunto(s)
Vacunas contra el Cólera/provisión & distribución , Cólera/inmunología , Cólera/prevención & control , Asociación entre el Sector Público-Privado , Administración Oral , Vacunas contra el Cólera/administración & dosificación , Vacunas contra el Cólera/uso terapéutico , India , República de Corea , Suecia , Vietnam
13.
Nat Rev Dis Primers ; 4(1): 8, 2018 07 12.
Artículo en Inglés | MEDLINE | ID: mdl-30002421

RESUMEN

Vibrio is a genus of ubiquitous bacteria found in a wide variety of aquatic and marine habitats; of the >100 described Vibrio spp., ~12 cause infections in humans. Vibrio cholerae can cause cholera, a severe diarrhoeal disease that can be quickly fatal if untreated and is typically transmitted via contaminated water and person-to-person contact. Non-cholera Vibrio spp. (for example, Vibrio parahaemolyticus, Vibrio alginolyticus and Vibrio vulnificus) cause vibriosis - infections normally acquired through exposure to sea water or through consumption of raw or undercooked contaminated seafood. Non-cholera bacteria can lead to several clinical manifestations, most commonly mild, self-limiting gastroenteritis, with the exception of V. vulnificus, an opportunistic pathogen with a high mortality that causes wound infections that can rapidly lead to septicaemia. Treatment for Vibrio spp. infection largely depends on the causative pathogen: for example, rehydration therapy for V. cholerae infection and debridement of infected tissues for V. vulnificus-associated wound infections, with antibiotic therapy for severe cholera and systemic infections. Although cholera is preventable and effective oral cholera vaccines are available, outbreaks can be triggered by natural or man-made events that contaminate drinking water or compromise access to safe water and sanitation. The incidence of vibriosis is rising, perhaps owing in part to the spread of Vibrio spp. favoured by climate change and rising sea water temperature.


Asunto(s)
Vibriosis/fisiopatología , Vibriosis/terapia , Antibacterianos/uso terapéutico , Cólera/complicaciones , Cólera/fisiopatología , Cólera/terapia , Vacunas contra el Cólera/uso terapéutico , Fluidoterapia/métodos , Humanos , Calidad de Vida/psicología , Oligoelementos/uso terapéutico , Vibrio/patogenicidad , Vibrio/virología , Vibriosis/complicaciones , Vibrio cholerae/patogenicidad , Vibrio cholerae/virología , Vibrio parahaemolyticus/patogenicidad , Vibrio parahaemolyticus/virología , Vibrio vulnificus/patogenicidad , Vibrio vulnificus/virología , Zinc/uso terapéutico
15.
PLoS Med ; 15(2): e1002509, 2018 02.
Artículo en Inglés | MEDLINE | ID: mdl-29485987

RESUMEN

BACKGROUND: Cholera prevention and control interventions targeted to neighbors of cholera cases (case-area targeted interventions [CATIs]), including improved water, sanitation, and hygiene, oral cholera vaccine (OCV), and prophylactic antibiotics, may be able to efficiently avert cholera cases and deaths while saving scarce resources during epidemics. Efforts to quickly target interventions to neighbors of cases have been made in recent outbreaks, but little empirical evidence related to the effectiveness, efficiency, or ideal design of this approach exists. Here, we aim to provide practical guidance on how CATIs might be used by exploring key determinants of intervention impact, including the mix of interventions, "ring" size, and timing, in simulated cholera epidemics fit to data from an urban cholera epidemic in Africa. METHODS AND FINDINGS: We developed a micro-simulation model and calibrated it to both the epidemic curve and the small-scale spatiotemporal clustering pattern of case households from a large 2011 cholera outbreak in N'Djamena, Chad (4,352 reported cases over 232 days), and explored the potential impact of CATIs in simulated epidemics. CATIs were implemented with realistic logistical delays after cases presented for care using different combinations of prophylactic antibiotics, OCV, and/or point-of-use water treatment (POUWT) starting at different points during the epidemics and targeting rings of various radii around incident case households. Our findings suggest that CATIs shorten the duration of epidemics and are more resource-efficient than mass campaigns. OCV was predicted to be the most effective single intervention, followed by POUWT and antibiotics. CATIs with OCV started early in an epidemic focusing on a 100-m radius around case households were estimated to shorten epidemics by 68% (IQR 62% to 72%), with an 81% (IQR 69% to 87%) reduction in cases compared to uncontrolled epidemics. These same targeted interventions with OCV led to a 44-fold (IQR 27 to 78) reduction in the number of people needed to target to avert a single case of cholera, compared to mass campaigns in high-cholera-risk neighborhoods. The optimal radius to target around incident case households differed by intervention type, with antibiotics having an optimal radius of 30 m to 45 m compared to 70 m to 100 m for OCV and POUWT. Adding POUWT or antibiotics to OCV provided only marginal impact and efficiency improvements. Starting CATIs early in an epidemic with OCV and POUWT targeting those within 100 m of an incident case household reduced epidemic durations by 70% (IQR 65% to 75%) and the number of cases by 82% (IQR 71% to 88%) compared to uncontrolled epidemics. CATIs used late in epidemics, even after the peak, were estimated to avert relatively few cases but substantially reduced the number of epidemic days (e.g., by 28% [IQR 15% to 45%] for OCV in a 100-m radius). While this study is based on a rigorous, data-driven approach, the relatively high uncertainty about the ways in which POUWT and antibiotic interventions reduce cholera risk, as well as the heterogeneity in outbreak dynamics from place to place, limits the precision and generalizability of our quantitative estimates. CONCLUSIONS: In this study, we found that CATIs using OCV, antibiotics, and water treatment interventions at an appropriate radius around cases could be an effective and efficient way to fight cholera epidemics. They can provide a complementary and efficient approach to mass intervention campaigns and may prove particularly useful during the initial phase of an outbreak, when there are few cases and few available resources, or in order to shorten the often protracted tails of cholera epidemics.


Asunto(s)
Vacunas contra el Cólera/uso terapéutico , Cólera/epidemiología , Cólera/terapia , Brotes de Enfermedades , Necesidades y Demandas de Servicios de Salud , Modelos Teóricos , Manejo de Caso/normas , Manejo de Caso/estadística & datos numéricos , Cólera/prevención & control , Simulación por Computador , Geografía , Implementación de Plan de Salud/normas , Necesidades y Demandas de Servicios de Salud/normas , Necesidades y Demandas de Servicios de Salud/estadística & datos numéricos , Humanos , Purificación del Agua/normas
17.
Artículo en Inglés | MEDLINE | ID: mdl-29413709

RESUMEN

We identify high risk clusters and measure their persistence in time and analyze spatial and population drivers of small area incidence over time. The geographically linked population and cholera surveillance data in Matlab, Bangladesh for a 10-year period were used. Individual level data were aggregated by local 250 × 250 m communities. A retrospective space-time scan statistic was applied to detect high risk clusters. Generalized estimating equations were used to identify risk factors for cholera. We identified 10 high risk clusters, the largest of which was in the southern part of the study area where a smaller river flows into a large river. There is persistence of local spatial patterns of cholera and the patterns are related to both the population composition and ongoing spatial diffusion from nearby areas over time. This information suggests that targeting interventions to high risk areas would help eliminate locally persistent endemic areas.


Asunto(s)
Cólera/epidemiología , Bangladesh/epidemiología , Cólera/prevención & control , Cólera/transmisión , Vacunas contra el Cólera/uso terapéutico , Humanos , Incidencia , Estudios Retrospectivos , Factores de Riesgo , Población Rural , Factores Socioeconómicos , Análisis Espacio-Temporal
18.
Am J Trop Med Hyg ; 97(4_Suppl): 37-42, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-29064362

RESUMEN

The devastating 2010 cholera epidemic in Haiti prompted the government to introduce oral cholera vaccine (OCV) in two high-risk areas of Haiti. We evaluated the direct costs associated with the government's first vaccine campaign implemented in August-September 2013. We analyzed data for major cost categories and assessed the efficiency of available campaign resources to vaccinate the target population. For a target population of 107,906 persons, campaign costs totaled $624,000 and 215,295 OCV doses were dispensed. The total vaccine and operational cost was $2.90 per dose; vaccine alone cost $1.85 per dose, vaccine delivery and administration $0.70 per dose, and vaccine storage and transport $0.35 per dose. Resources were greater than needed-our analyses suggested that approximately 2.5-6 times as many persons could have been vaccinated during this campaign without increasing the resources allocated for vaccine delivery and administration. These results can inform future OCV campaigns in Haiti.


Asunto(s)
Vacunas contra el Cólera/uso terapéutico , Cólera/prevención & control , Administración Oral , Cólera/epidemiología , Vacunas contra el Cólera/economía , Costos y Análisis de Costo , Brotes de Enfermedades , Programas de Gobierno/economía , Haití/epidemiología , Humanos , Programas de Inmunización/economía
19.
Int J Epidemiol ; 46(6): 2056-2066, 2017 12 01.
Artículo en Inglés | MEDLINE | ID: mdl-29025064

RESUMEN

Background: Information on the impact of hygiene interventions on severe outcomes is limited. As a pre-specified secondary outcome of a cluster-randomized controlled trial among >400 000 low-income residents in Dhaka, Bangladesh, we examined the impact of cholera vaccination plus a behaviour change intervention on diarrhoea-associated hospitalization. Methods: Ninety neighbourhood clusters were randomly allocated into three areas: cholera-vaccine-only; vaccine-plus-behaviour-change (promotion of hand-washing with soap plus drinking water chlorination); and control. Study follow-up continued for 2 years after intervention began. We calculated cluster-adjusted diarrhoea-associated hospitalization rates using data we collected from nearby hospitals, and 6-monthly census data of all trial households. Results: A total of 429 995 people contributed 500 700 person-years of data (average follow-up 1.13 years). Vaccine coverage was 58% at the start of analysis but continued to drop due to population migration. In the vaccine-plus-behaviour-change area, water plus soap was present at 45% of hand-washing stations; 4% of households had detectable chlorine in stored drinking water. Hospitalization rates were similar across the study areas [events/1000 person-years, 95% confidence interval (CI), cholera-vaccine-only: 9.4 (95% CI: 8.3-10.6); vaccine-plus-behaviour-change: 9.6 (95% CI: 8.3-11.1); control: 9.7 (95% CI: 8.3-11.6)]. Cholera cases accounted for 7% of total number of diarrhoea-associated hospitalizations. Conclusions: Neither cholera vaccination alone nor cholera vaccination combined with behaviour-change intervention efforts measurably reduced diarrhoea-associated hospitalization in this highly mobile population, during a time when cholera accounted for a small fraction of diarrhoea episodes. Affordable community-level interventions that prevent infection from multiple pathogens by reliably separating faeces from the environment, food and water, with minimal behavioural demands on impoverished communities, remain an important area for research.


Asunto(s)
Vacunas contra el Cólera/uso terapéutico , Cólera/epidemiología , Cólera/prevención & control , Desinfección de las Manos/métodos , Hospitalización/estadística & datos numéricos , Purificación del Agua/métodos , Adolescente , Adulto , Anciano , Bangladesh/epidemiología , Niño , Preescolar , Análisis por Conglomerados , Diarrea/etiología , Composición Familiar , Heces/microbiología , Femenino , Humanos , Lactante , Masculino , Persona de Mediana Edad , Modelos de Riesgos Proporcionales , Vacunación/estadística & datos numéricos , Vibrio cholerae/aislamiento & purificación , Microbiología del Agua , Adulto Joven
20.
Vaccine ; 35(37): 5043-5049, 2017 09 05.
Artículo en Inglés | MEDLINE | ID: mdl-28765003

RESUMEN

BACKGROUND: Cholera remains a threat globally, and socioeconomic factors play an important role in transmission of the disease. We assessed socioeconomic risk factors for cholera in vaccinated and non-vaccinated communities to understand whether the socioeconomic risk factors differ by transmission patterns for cholera. METHODS: We used data from a cluster randomized control trial conducted in Dhaka, Bangladesh. There were 90 geographic clusters; 30 in each of the three arms of the study: vaccine (VAC), vaccine plus behavioural change (VBC), and non-intervention. The data were analysed for the three populations: (1) vaccinees in the vaccinated communities (VAC and VBC arms), (2) non-vaccinated individuals in the vaccinated communities and (3) all individuals in the non-vaccinated communities (non-intervention arm). A generalized estimating equation with logit link function was used to evaluate the risk factors for cholera among these different populations adjusting for household level correlation in the data. RESULTS: A total of 528 cholera and 226 cholera with severe dehydration (CSD) in 268,896 persons were observed during the two-year follow-up. For population 1, the cholera risk was not associated with any socioeconomic factors; however CSD was less likely to occur among individuals living in a household having ≤4 members (aOR=0.55, 95% CI=0.32-0.96). Among population 2, younger participants and individuals reporting diarrhoea during registration were more likely to have cholera. Females and individuals reporting diarrhoea during registration were at increased risk of CSD. Among population 3, individuals living in a household without a concrete floor, in an area with high population density, closer to the study hospital, or not treating drinking water were at significantly higher risk for both cholera and CSD. CONCLUSION: The profile of socioeconomic factors associated with cholera varies by individuals' vaccination status as well as the transmission setting. In a vaccinated community where transmission would be expected to be lower, socioeconomic factors may not increase the risk of the disease.


Asunto(s)
Vacunas contra el Cólera/uso terapéutico , Cólera/inmunología , Cólera/prevención & control , Administración Oral , Adolescente , Adulto , Bangladesh , Niño , Preescolar , Cólera/transmisión , Vacunas contra el Cólera/administración & dosificación , Vacunas contra el Cólera/inmunología , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Factores de Riesgo , Factores Socioeconómicos , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...